<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJEMD</journal-id><journal-title-group><journal-title>Open Journal of Endocrine and Metabolic Diseases</journal-title></journal-title-group><issn pub-type="epub">2165-7424</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojemd.2023.1312018</article-id><article-id pub-id-type="publisher-id">OJEMD-130075</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Evaluation of Plasma Malondialdehyde among Sudanese Type 2 Diabetic Patients
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gad</surname><given-names>Allah Modawe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ibtihal</surname><given-names>Elamin Mohammed</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abuagla</surname><given-names>M. Dafalla</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdelmarouf</surname><given-names>Mohieldein</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Medical Laboratory Sciences, Department of Clinical Chemistry, National University, Khartoum, Sudan</addr-line></aff><aff id="aff1"><addr-line>Faculty of Medicine and Health Sciences, Department of Biochemistry, Omdurman Islamic University, Omdurman, Sudan</addr-line></aff><aff id="aff4"><addr-line>College of Applied Medical Sciences, Department of Medical Laboratories, Qassim University, Buraidah, 
Kingdom of Saudi Arabia</addr-line></aff><aff id="aff3"><addr-line>Faculty of Medical Laboratory Sciences, Department of Clinical Chemistry, University of Gezira, WadMadani, Sudan</addr-line></aff><pub-date pub-type="epub"><day>26</day><month>12</month><year>2023</year></pub-date><volume>13</volume><issue>12</issue><fpage>234</fpage><lpage>243</lpage><history><date date-type="received"><day>27,</day>	<month>October</month>	<year>2023</year></date><date date-type="rev-recd"><day>24,</day>	<month>December</month>	<year>2023</year>	</date><date date-type="accepted"><day>27,</day>	<month>December</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background and objectives
  : Diabetes is a chronic multifactorial disease
   which requires a variety of strategies to reduce its epidemic. Type 2 diabetes (T2MD) is the most common form of diabetes which results from inefficiency of insulin secretion or resistance to insulin action, both of which lead to chronic hyperglycemia. Lipid peroxidation is an oxidative stress process that involve in T2DM complications. This study aimed to 1) determine plasma malondialdehyde (MDA) levels as a biomarker for lipid peroxidation in Sudanese patients with T2DM, and 2) assess the associations between MDA and diabetes-related variables. <b>Material and Methods</b>: This case-control study was conducted from November 2022 to June 2023 at the National University, Sudan. It included 100 participants, of whom 50 were T2DM patients and 50 were healthy controls. Data on demographics, clinical characteristics, and biochemical markers (FBS, HbA1c, and MDA) were collected. The NycoCard HbA1c method and the GOD-POD Method were used for HbA1c and glucose measurement, respectively. MDA was determined by the thiobarbituric acid reactive substances method. The data were analyzed using SPSS Version. <b>Results</b>: Significant differences were observed between T2DM patients and healthy controls in FBS (P = 0.000), HbA1c (P = 0.000), and MDA (P = 0.010), with T2DM patients exhibiting higher levels. The study revealed a strong positive correlation between MDA levels and the duration of diabetes (r = 0.69, P = 0.00), while other variables, including age, BMI, and glucose control, did not significantly correlate with MDA levels. <b>Conclusion</b>: Findings revealed elevated MDA levels in Sudanese T2DM patients, with a positive correlation between MDA and diabetes duration. These findings emphasize the importance of oxidative stress in T2DM pathogenesis and call for the need for targeted strategies to mitigate oxidative damage and improve diabetes care.
 
</p></abstract><kwd-group><kwd>Lipid Peroxide</kwd><kwd> Malondialdehyde</kwd><kwd> Hyperglycemia</kwd><kwd> Type 2 Diabetes Mellitus</kwd><kwd> Sudanese</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Diabetes mellitus (DM) is a chronic, multifactorial health disorder that results from either inadequate insulin secretion or impaired insulin utilization [<xref ref-type="bibr" rid="scirp.130075-ref1">1</xref>] . DM is caused by genetic and/or environmental factors [<xref ref-type="bibr" rid="scirp.130075-ref2">2</xref>] . The prevalence of DM, as reported by the International Diabetes Federation, is anticipated to increase from 10.5% in 2021 to 11.3% by 2030 and 12.2% by 2040 [<xref ref-type="bibr" rid="scirp.130075-ref3">3</xref>] . According to the 2019 Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), DM was ranked in the eighth position for causes leading to mortality and morbidity worldwide [<xref ref-type="bibr" rid="scirp.130075-ref4">4</xref>] .</p><p>Type 2 diabetes mellitus (T2DM), also known as “noninsulin-dependent diabetes” or “adult-onset diabetes,” accounts for around 90% - 95% of all occurrences of DM [<xref ref-type="bibr" rid="scirp.130075-ref5">5</xref>] . T2DM has substantial economic and social consequences [<xref ref-type="bibr" rid="scirp.130075-ref6">6</xref>] . Microvascular and macrovascular complications are both more likely in patients with T2DM [<xref ref-type="bibr" rid="scirp.130075-ref7">7</xref>] . Around 54% of diabetics in Africa went undiagnosed, and 416 thousand deaths in 2021 were caused by diabetes-related complications [<xref ref-type="bibr" rid="scirp.130075-ref8">8</xref>] .</p><p>Lipid peroxidation is a chemical process that occurs when free radicals or other reactive substances combine with polyunsaturated fatty acids leading to the production of lipid peroxyl radicals and hydroperoxides which damage the human cells [<xref ref-type="bibr" rid="scirp.130075-ref9">9</xref>] . Cell damage induced by oxidative stress ultimately results in complications of diabetes [<xref ref-type="bibr" rid="scirp.130075-ref10">10</xref>] . Malondialdehyde (MDA), a lipid peroxidation byproduct, is a reliable biomarker for oxidative stress [<xref ref-type="bibr" rid="scirp.130075-ref11">11</xref>] .</p><p>In the Sudanese population diagnosed with T2DM, there was limited research that explored biomarkers of oxidative stress. Therefore, we aimed to 1) assess plasma MDL levels as a biomarker for lipid peroxidation in Sudanese patients with T2DM, 2) examine the relationships between MDA levels and selected variables associated with type 2 diabetes.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Study Design</title><p>An age- and sex-matched hospital-based, case-control study was conducted at the National University, Faculty of Medical Laboratory Sciences in Khartoum, Sudan, from November 2022 to June 2023.</p></sec><sec id="s2_2"><title>2.2. Study Population and Data Collection</title><p>One hundred Sudanese individuals were enrolled. They were divided into two groups: the case group consisted of 50 type 2 diabetic patients, and the control group consisted of 50 healthy individuals. The patients were recruited from the diabetes center at Yastabshiron Hospital in Khartoum, Sudan, whereas healthy individuals were randomly selected from the community. Inclusion criteria: ambulatory type 2 diabetic patients, male or female, do not have any diabetic complications. Exclusion criteria: patients with type 1 diabetes or patients with type 2 diabetes who had comorbidities, renal impairment, metabolic abnormalities, smoking habits, liver illness, or other diabetes-related complications.</p><p>Patients with T2DM were diagnosed according to guidelines from the World Health Organization (WHO). Diabetes was established when an overnight fasting plasma glucose level of ≥126 mg/dL [<xref ref-type="bibr" rid="scirp.130075-ref12">12</xref>] .</p><p>A structured questionnaire was developed with the purpose of gathering both personal and medical information, such as the participant’s age, gender, disease duration, and current undertaken medication for diabetes.</p></sec><sec id="s2_3"><title>2.3. Blood Sampling &amp; Plasma Preparation</title><p>5 ml of fasting venous blood was collected from each subject in heparin vacutainers. To extract the plasma, whole blood in the heparin vacutainers was centrifuged at 3000 RPM for 15 minutes. The plasma was placed in a sterile container and stored at 8˚C until starting the experiments.</p></sec><sec id="s2_4"><title>2.4. Anthropometric Measures</title><p>The weight and height of each subject were carefully assessed and documented. Weight was measured using an electronic weighing scale, and height measurement was recorded using a stadiometer. We computed body mass index (BMI) as body weight in kilograms divided by height in meters squared. Participants with a BMI equal to 25 - 29.9 kg/m<sup>2</sup> were defined as overweight, while those with a BMI ≥ 30.0 kg/m<sup>2</sup> were defined as obese according to the WHO definition.</p></sec><sec id="s2_5"><title>2.5. Estimation of Biochemical Parameters</title><p>The glucose oxidase-peroxidase (GOD-POD) method was used to measure plasma glucose levels on a COBAS INTEGRA 400 using kits purchased from Roche Diagnostics. Briefly, the glucose in the samples was oxidized by glucose oxidase to produce gluconic acid and hydrogen peroxide. The hydrogen peroxide was broken down into oxygen and water by a peroxidase enzyme. The oxygen then reacted with the oxygen acceptor orthotoluidine, which converted into a colored compound, the amount of which was measured colorimetrically.</p><p>The NycoCard HbA1c method was employed to determine the levels of glycated hemoglobin (HbA1c). Briefly, a monoclonal antibody binds to HbA1c, resulting in the formation of an immune complex whose intensity of color change is directly proportional to the HbA1c concentration.</p><p>Plasma malondialdehyde (MDA) was estimated by the spectrophotometric method using an MDA commercial kit purchased from a Bio diagnostic company. MDA was assessed by the thiobarbituric acid reactive substances (TBARS) method. Briefly, thiobarbituric acid (TBA) reacts with MDA in acidic medium at a temperature of 95˚C for 30 min to form a pink thiobarbituric acid reactive product (TBARS) which was measured at 534 nm using a spectrophotometer.</p></sec><sec id="s2_6"><title>2.6. Data Analysis</title><p>The Statistical Package for Social Science (SPSS Inc., Chicago, Illinois, USA) version 25.0 software was utilized for data analysis. Continuous data were presented as mean &#177; SD (range), while categorical data were expressed as the number (%). A comparison of variables between patients and healthy controls was performed with an unpaired t-test for continuous data and a chi-square for categorical data. The Pearson coefficient correlation was used to examine the relationship between MDA and selected variables. The level of significance was considered when the P-value &lt; 0.05.</p></sec><sec id="s2_7"><title>2.7. Ethical Considerations</title><p>The National University Research Ethics Committee (NU-REC) at the National University in Khartoum, Sudan, gave its approval for the study under approval number NU-REC/13-022/10.</p><p>The study was conducted according to the principles of the Helsinki Declaration. Participation was voluntary, and verbal consent was obtained from each participant. The confidentiality of all participants was maintained as no names were requested.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Characteristics of Study Participants</title><p>Data analysis (<xref ref-type="table" rid="table1">Table 1</xref>) indicates that there was no significant difference in age, gender, weight, and BMI distributions between the cases and healthy controls, as indicated by P-values of 0.104, 0.423, 0.924, and 0.213, respectively. However, a significant difference was observed in height, where the control group exhibited a significantly lower mean height compared to the case group (P = 0.021). The duration of diabetes in the case group had a mean of 13.33 years, with a range from 1 to 27 years. A significant number of the diabetic patients were on antidiabetic tablets for treatment, and a small percentage were on insulin.</p></sec><sec id="s3_2"><title>3.2. Measurement of Biochemical Markers</title><p>Significant differences in the key biochemical markers between the case and control groups were documented (<xref ref-type="table" rid="table2">Table 2</xref>). Firstly, FBS levels in the case group were significantly higher, with a mean of 156.66 mg/dL, compared to the control group’s mean of 82.64 mg/dL (P = 0.000). This difference indicates impaired glucose control in the case group, which is a characteristic feature of diabetes. Additionally, the average HbA1c percentage was significantly elevated in the case group, with a mean of 8.56%, while the control group displayed 4.97% (P = 0.000). The</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Demographic characteristics of diabetic and control participants</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Cases (n = 50)</th><th align="center" valign="middle" >Controls (n = 50)</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle" >M:F ratio</td><td align="center" valign="middle" >26:24</td><td align="center" valign="middle" >22:28</td><td align="center" valign="middle" >0.423</td></tr><tr><td align="center" valign="middle" >Age; years</td><td align="center" valign="middle" >52.92 &#177; 8.7 (40 - 74)</td><td align="center" valign="middle" >50.28 &#177; 7.9 (38 - 70)</td><td align="center" valign="middle" >0.104</td></tr><tr><td align="center" valign="middle" >Weight, Kg</td><td align="center" valign="middle" >74.06 &#177; 6.1</td><td align="center" valign="middle" >74.18 &#177; 6.4</td><td align="center" valign="middle" >0.924</td></tr><tr><td align="center" valign="middle" >Height, cm</td><td align="center" valign="middle" >163.50 &#177; 5.5</td><td align="center" valign="middle" >161.04 &#177; 5.1</td><td align="center" valign="middle" >0.021*</td></tr><tr><td align="center" valign="middle" >BMI; kg/m<sup>2</sup></td><td align="center" valign="middle" >27.52 &#177; 3.0 (18.8 - 33.1)</td><td align="center" valign="middle" >28.36 &#177; 3.0 (23 - 31)</td><td align="center" valign="middle" >0.213</td></tr><tr><td align="center" valign="middle" >Duration DM; years</td><td align="center" valign="middle" >13.33 &#177; 6.9 (1 - 27)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Treatment; n (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Insulin</td><td align="center" valign="middle" >3 (6)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.000*</td></tr><tr><td align="center" valign="middle" >Tablets</td><td align="center" valign="middle" >34 (68)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Tablets + insulin</td><td align="center" valign="middle" >13 (26)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap><p>BMI, body mass index; DM, diabetes mellitus; F, female; M, male. Data presented as mean &#177; SD (min-max) for continuous variables or number (%) for categorical variables; *P value less than 0.05 was considered statistically significant.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Biochemical characteristics of diabetic and control participants</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Case</th><th align="center" valign="middle" >Control</th><th align="center" valign="middle" >P-value</th></tr></thead><tr><td align="center" valign="middle" >FBS; mg/dL</td><td align="center" valign="middle" >157.660 &#177; 68.5</td><td align="center" valign="middle" >82.64 &#177; 24.1</td><td align="center" valign="middle" >0.000*</td></tr><tr><td align="center" valign="middle" >HbA1c; %</td><td align="center" valign="middle" >8.56 &#177; 1.8</td><td align="center" valign="middle" >4.97 &#177; 1.6</td><td align="center" valign="middle" >0.000*</td></tr><tr><td align="center" valign="middle" >MDA, nmol/ml</td><td align="center" valign="middle" >1.83 &#177; 0.3</td><td align="center" valign="middle" >1.01 &#177; 0.2</td><td align="center" valign="middle" >0.010*</td></tr></tbody></table></table-wrap><p>FBS, fasting blood sugar; HbA1c, glycosylated haemoglobin; MDA, malondialdehyde. Data presented as mean &#177; SD; *P value less than 0.05 was considered statistically significant.</p><p>elevated HbA1c levels in the case group reflect the prolonged hyperglycemia, which is a hallmark of poor glycemic control in diabetes. Moreover, plasma MDA levels, a marker of oxidative stress, were significantly higher in the case group with a mean of 1.83 nmol/ml, compared to the control group’s mean of 1.01 nmol/ml (P = 0.000). This elevated MDA suggests increased oxidative stress in diabetic patients, likely resulting from the metabolic disturbances associated with diabetes.</p></sec><sec id="s3_3"><title>3.3. Relation between MDA and Selected Variables</title><p>As presented in <xref ref-type="table" rid="table3">Table 3</xref>, the Pearson coefficient analysis revealed a significant strong positive correlation between the duration of diabetes and plasma MDA levels (r = 0.69, P = 0.00). This finding highlights that, with the prolonged duration of diabetes, there is a significant increase in oxidative stress, as evidenced by elevated MDA levels. Conversely, other variables, including age, height, weight, BMI, and markers of short-term glucose control such as FBG and HbA1c, did not demonstrate significant correlations with MDA levels. These findings highlight the substantial impact of chronic diabetes on oxidative stress and underscores</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Correlation between malondialdehyde (MDA) and age, Body max index (BMI), duration of disease, fasting blood glucose (FBG) and glycosylated haemoglobin (HbA1c) in all participants</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variable</th><th align="center" valign="middle" >MDA</th></tr></thead><tr><td align="center" valign="middle" >Age</td><td align="center" valign="middle" >r = −0.282</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >P = 0.470</td></tr><tr><td align="center" valign="middle" >Height</td><td align="center" valign="middle" >r = 0.057</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >P = 0.693</td></tr><tr><td align="center" valign="middle" >Weight</td><td align="center" valign="middle" >r = 0.236</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >P = 0.099</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >r = −0.190</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >P = 0.180</td></tr><tr><td align="center" valign="middle" >Duration of disease</td><td align="center" valign="middle" >r = 0.69</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >P = 0.00*</td></tr><tr><td align="center" valign="middle" >FBG</td><td align="center" valign="middle" >r = −0.122</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >P = 0.58</td></tr><tr><td align="center" valign="middle" >HbA1c</td><td align="center" valign="middle" >R = 0.210</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >P = 0.32</td></tr></tbody></table></table-wrap><p>FBS, fasting blood sugar; HbA1c, glycosylated haemoglobin; MDA, malondialdehyde; BMI, body mass index. *Correlation is significant at the 0.05 level (2-tailed).</p><p>the role of chronic hyperglycemia as a significant factor in enhancing oxidative stress in patients with diabetes.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>Findings from this study reveal significantly elevated plasma MDA levels in Sudanese patients with type 2 diabetes compared to healthy individuals. This aligns with various published research conducted among different populations worldwide. There was a significant increase (P = 0.004) in MDA levels observed in South African individuals with type 2 diabetes (n = 57) compared to healthy controls (n = 41), with respective measurements of 4.33 μM and 3.43 μM [<xref ref-type="bibr" rid="scirp.130075-ref13">13</xref>] . Moreover, a case-control study conducted on an Indonesian population revealed higher MDA levels in diabetes patients (n = 40) with median values of 2.43 μM compared to non-diabetic individuals (n = 40) with median values of 1.69 μM, respectively (P = 0.000) [<xref ref-type="bibr" rid="scirp.130075-ref14">14</xref>] . In a study of Iraqi Arab females with type 2 diabetes mellitus (n = 51) and control subjects (n = 31), serum MDA was significantly elevated in diabetic patients at 6.78 &#177; 1.21 nmol/ml compared to controls at 3.82 &#177; 0.77 nmol/ml (p &lt; 0.001) [<xref ref-type="bibr" rid="scirp.130075-ref15">15</xref>] . Among Indian participants, MDA levels were significantly higher in type 2 diabetic patients (n = 100) compared to non-diabetic individuals (n = 100), with measurements of 5.9 &#177; 1.6 μmol/L and 1.8 &#177; 0.6 μmol/L, respectively (P = 0.029) [<xref ref-type="bibr" rid="scirp.130075-ref16">16</xref>] . Another study involving 139 Nigerian men and women found that serum malondialdehyde levels were elevated in type 2 diabetes patients, measuring 2.1 &#177; 0.1 μmol/L, compared to control subjects at 0.7 &#177; 0.0 μmol/L (P = 0.01) [<xref ref-type="bibr" rid="scirp.130075-ref17">17</xref>] . Additionally, in Iranian population; female patients exhibited significantly higher MDA levels (2.57 &#177; 1.38 nmol/ml) than their male counterparts (2.10 &#177; 0.67 nmol/ml), whereas male patients showed increased MDA levels (2.10 &#177; 0.67 nmol/ml) compared to male controls (1.14 &#177; 0.7 nmol/ml). Similarly, female patients displayed significantly higher MDA levels (2.57 &#177; 1.38 nmol/ml) compared to female controls (1.07 &#177; 0.39 nmol/ml) [<xref ref-type="bibr" rid="scirp.130075-ref18">18</xref>] . These findings collectively emphasize the association between MDA and type 2 diabetes across diverse populations.</p><p>Furthermore, the study documented a strong positive correlation between MDA levels and the duration of the disease, indicating that as diabetes advances, oxidative stress increases. This supports the concept that extended exposure to high blood sugar levels increases the likelihood of oxidative damage [<xref ref-type="bibr" rid="scirp.130075-ref19">19</xref>] . The lack of a significant correlation between MDA levels and fasting blood glucose and HbA1C might be surprising. Although high blood glucose is recognized for its role in oxidative stress, the complex relationship between glucose control and oxidative stress may not consistently result in a direct correlation. Other variables, like dietary habits and individual variation, could independently impact MDA levels [<xref ref-type="bibr" rid="scirp.130075-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.130075-ref21">21</xref>] .</p><p>The clinical implications of the elevated MDA levels observed in diabetic patients are important. As indicated by an elevated MDA, oxidative stress is linked to a variety of diabetic microvascular and macrovascular complications. For example, it exerts a substantial influence on the progression and onset of microvascular complications, including diabetic nephropathy, retinopathy, and neuropathy [<xref ref-type="bibr" rid="scirp.130075-ref22">22</xref>] . Furthermore, increased MDA levels may worsen insulin resistance, resulting in a vicious cycle that may have an adverse effect on glycemic control and overall health [<xref ref-type="bibr" rid="scirp.130075-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.130075-ref24">24</xref>] . Chronic hyperglycemia causes oxidative stress, which in turn causes lipid peroxidation by promoting the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) [<xref ref-type="bibr" rid="scirp.130075-ref25">25</xref>] . When lipid peroxidation begins, it sets off a sequence of chain reactions that continue until termination byproducts are produced, one of which is lipid hydroperoxide. These hydroperoxides subsequently break down into aldehydes, such as MDA [<xref ref-type="bibr" rid="scirp.130075-ref9">9</xref>] . The rise in MDA levels among patients with type 2 diabetes in this study can be attributed to the elevated production of lipid peroxides and their release into the bloodstream.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In conclusion, this study highlights the elevated MDA levels in Sudanese patients with type 2 diabetes and the correlation between the raised MDA levels and disease duration, especially in patients who have had the disease for a longer period of time. These findings underline the need for diabetes care techniques to reduce oxidative stress which has a crucial role in the pathogenesis of diabetes complications.</p></sec><sec id="s6"><title>6. Limitation</title><p>We did not measure parameters of lipid profile, including total cholesterol, LDL, HDL, and triglycerides. Specific lipid alterations can influence the production of reactive oxygen species, potentially impacting MDA levels. Future studies may consider including lipid profile assessments to gain a more comprehensive understanding of oxidative stress mechanisms in type 2 diabetes.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="s8"><title>Cite this paper</title><p>Modawe, G.A., Mohammed, I.E., Dafalla, A.M. and Mohieldein, A. (2023) Evaluation of Plasma Malondialdehyde among Sudanese Type 2 Diabetic Patients. Open Journal of Endocrine and Metabolic Diseases, 13, 234-243. https://doi.org/10.4236/ojemd.2023.1312018</p></sec></body><back><ref-list><title>References</title><ref id="scirp.130075-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Dawite, F., Girma, M., Shibiru, T., Kefelew, E., Hailu, T., Temesgen, R. and Abebe, G. (2023) Factors Associated with Poor Glycemic Control among Adult Patients with Type 2 Diabetes Mellitus in Gamo and Gofa Zone Public Hospitals, Southern Ethiopia: A Case-Control Study. PLOS ONE, 18, e0276678. https://doi.org/10.1371/journal.pone.0276678</mixed-citation></ref><ref id="scirp.130075-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Artasensi, A., Pedretti, A., Vistoli, G. and Fumagalli, L. (2020) Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules, 25, Article No. 1987. https://doi.org/10.3390/molecules25081987</mixed-citation></ref><ref id="scirp.130075-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ye, J., Wu, Y., Yang, S., Zhu, D., Chen, F., Chen, J., Ji, X. and Hou, K. (2023) The Global, Regional and National Burden of Type 2 Diabetes Mellitus in the Past, Present and Future: A Systematic Analysis of the Global Burden of Disease Study 2019. Frontiers in Endocrinology (Lausanne), 14, Article ID: 1192629. https://doi.org/10.3389/fendo.2023.1192629</mixed-citation></ref><ref id="scirp.130075-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ong, K.L., Stafford, L.K., McLaughlin, S.A., Boyko, E.J., Vollset, S.E., Smith, A.E., et al. (2023) Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet, 402, 203-234.</mixed-citation></ref><ref id="scirp.130075-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">American Diabetes Association Professional Practice Committee (2022) 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. Diabetes Care, 45, S17-S38. https://doi.org/10.2337/dc22-S002</mixed-citation></ref><ref id="scirp.130075-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">O’Hearn, M., Lara-Castor, L., Cudhea, F., Miller, V., Reedy, J., Shi, P., et al. (2023) Incident Type 2 Diabetes Attributable to Suboptimal Diet in 184 Countries. Nature Medicine, 29, 982-995. https://doi.org/10.1038/s41591-023-02278-8</mixed-citation></ref><ref id="scirp.130075-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kanumilli, N., Butler, J., Makrilakis, K., Rydén, L., Vallis, M., Wanner, C., et al. (2023) Guardians for Health: A Practical Approach to Improving Quality of Life and Longevity in People with Type 2 Diabetes. Diabetes Therapy, 14, 1093-1110. https://doi.org/10.1007/s13300-023-01418-0</mixed-citation></ref><ref id="scirp.130075-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ogbole, F.A. and Harold, B.A. (2023) Association of Undiagnosed Pre-Diabetes and Type-2 Diabetes Mellitus with Interleukin-2 mRNA Expression among Adults in Bayelsa State, Nigeria. IJRR, 10, 210-215. https://www.ijrrjournal.com/IJRR_Vol.10_Issue.5_May2023/IJRR-Abstract25.html https://doi.org/10.52403/ijrr.20230525</mixed-citation></ref><ref id="scirp.130075-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ayala, A., Mu&amp;#241;oz, M.F. and Argüelles, S. (2014) Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. Oxidative Medicine and Cellular Longevity, 2014, Article ID: 360438. https://doi.org/10.1155/2014/360438</mixed-citation></ref><ref id="scirp.130075-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Morsi, H.K., Ismail, M.M., Gaber, H.A. and Elbasmy, A.A. (2016) Macrophage Migration Inhibitory Factor and Malondialdehyde as Potential Predictors of Vascular Risk Complications in Type 2 Diabetes Mellitus: Cross-Sectional Case-Control Study in Saudi Arabia. Mediators of Inflammation, 2016, Article ID: 5797930. https://doi.org/10.1155/2016/5797930</mixed-citation></ref><ref id="scirp.130075-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, F., Zhou, L., Zhang, C., Jiang, H. and Xu, Z. (2023) Malondialdehyde Levels in Diabetic Retinopathy Patients: A Systematic Review and Meta-Analysis. Chinese Medical Journal, 136, 1311-1321. https://doi.org/10.1097/CM9.0000000000002620</mixed-citation></ref><ref id="scirp.130075-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kasujja, F.X., Mayega, R.W., Daivadanam, M., Kiracho, E.E., Kusolo, R. and Nuwaha, F. (2022) Glycated Haemoglobin and Fasting Plasma Glucose Tests in the Screening of Outpatients for Diabetes and Abnormal Glucose Regulation in Uganda: A Diagnostic Accuracy Study. PLOS ONE, 17, e0272515. https://doi.org/10.1371/journal.pone.0272515</mixed-citation></ref><ref id="scirp.130075-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ganjifrockwala, F.A., Joseph, J.T. and George, G. (2017) Decreased Total Antioxidant Levels and Increased Oxidative Stress in South African Type 2 Diabetes Mellitus Patients. Journal of Endocrinology, Metabolism and Diabetes of South Africa, 22, 21-25. https://doi.org/10.1080/16089677.2017.1324590</mixed-citation></ref><ref id="scirp.130075-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Sunita, R., Sahidan, S. and Hidayat, R. (2020) Evaluation of Malondialdehyde in Type 2 Diabetes Mellitus Patients as Oxidative Stress Markers in Bengkulu Population. Bioscientia Medicina: Journal of Biomedicine and Translational Research, 4, 45-54. https://doi.org/10.32539/bsm.v4i3.146</mixed-citation></ref><ref id="scirp.130075-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Alaaraji Shakir, F., Alrawi Khalid, F., Saif Allah Perry, H. and Alkrwi Esam, N. (2016) Evaluation of Serum Malondialdehyde, Glutathione and Lipid Profile Levels in Iraqi Females with Type 2 Diabetes Mellitus. Baghdad Science Journal, 13, 383-391. https://doi.org/10.21123/bsj.2016.13.2.2NCC.0383</mixed-citation></ref><ref id="scirp.130075-ref16"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Singh</surname><given-names> M. </given-names></name>,<etal>et al</etal>. (<year>2020</year>)<article-title>High-Sensitivity C-Reactive Protein, Malondialdehyde and Their Association with Glycated Hemoglobin (HbA1c) in Type 2 Diabetes Patients</article-title><source> International Journal of Health and Clinical Research</source><volume> 3</volume>,<fpage> 81</fpage>-<lpage>86</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.130075-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Lawal, N., Akuyam, S.A. and Ahmad, M.B. (2022) Relationship between Serum Malondialdehyde (MDA) Levels and Cardiovascular Risk Factors in Diabetic Patients in Zaria, Kaduna State, Nigeria. BJMLS, 7, 41-50.</mixed-citation></ref><ref id="scirp.130075-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Marjani, A., Veghari, G. and Badeleh, M.T. (2009) Serum Lipid Peroxidation and Leptin Levels in Male and Female Type 2 Diabetic Patients in Gorgan (South East of Caspian Sea), Iran. Journal of Chinese Clinical Medicine, 5, 26-35.</mixed-citation></ref><ref id="scirp.130075-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Iacobini, C., Vitale, M., Pesce, C., Pugliese, G. and Menini, S. (2021) Diabetic Complications and Oxidative Stress: A 20-Year Voyage Back in Time and Back to the Future. Antioxidants (Basel), 10, Article No. 727. https://doi.org/10.3390/antiox10050727</mixed-citation></ref><ref id="scirp.130075-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Saieva, C., Peluso, M., Palli, D., Cellai, F., Ceroti, M., Selvi, V., et al. (2016) Dietary and Lifestyle Determinants of Malondialdehyde DNA Adducts in a Representative Sample of the Florence City Population. Mutagenesis, 31, 475-480. https://doi.org/10.1093/mutage/gew012</mixed-citation></ref><ref id="scirp.130075-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Aleksandrova, K., Koelman, L. and Rodrigues, C.E. (2021) Dietary Patterns and Biomarkers of Oxidative Stress and Inflammation: A Systematic Review of Observational and Intervention Studies. Redox Biology, 42, Article ID: 101869. https://doi.org/10.1016/j.redox.2021.101869</mixed-citation></ref><ref id="scirp.130075-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Perng, W., Conway, R., Mayer-Davis, E. and Dabelea, D. (2023) Youth-Onset Type 2 Diabetes: The Epidemiology of an Awakening Epidemic. Diabetes Care, 46, 490-499. https://doi.org/10.2337/dci22-0046</mixed-citation></ref><ref id="scirp.130075-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Tangvarasittichai, S. (2015) Oxidative Stress, Insulin Resistance, Dyslipidemia and Type 2 Diabetes Mellitus. World Journal of Diabetes, 6, 456-480. https://doi.org/10.4239/wjd.v6.i3.456</mixed-citation></ref><ref id="scirp.130075-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Szukiewicz, D. (2023) Molecular Mechanisms for the Vicious Cycle between Insulin Resistance and the Inflammatory Response in Obesity. International Journal of Molecular Sciences, 24, Article No. 9818. https://doi.org/10.3390/ijms24129818</mixed-citation></ref><ref id="scirp.130075-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Masenga, S.K., Kabwe, L.S., Chakulya, M. and Kirabo, A. (2023) Mechanisms of Oxidative Stress in Metabolic Syndrome. International Journal of Molecular Sciences, 24, Article No. 7898. https://doi.org/10.3390/ijms24097898</mixed-citation></ref></ref-list></back></article>